Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
2.
Genome Med ; 14(1): 62, 2022 06 13.
Article in English | MEDLINE | ID: mdl-35698242

ABSTRACT

BACKGROUND: Genomics enables individualized diagnosis and treatment, but large challenges remain to functionally interpret rare variants. To date, only one causative variant has been described for KCNK9 imprinting syndrome (KIS). The genotypic and phenotypic spectrum of KIS has yet to be described and the precise mechanism of disease fully understood. METHODS: This study discovers mechanisms underlying KCNK9 imprinting syndrome (KIS) by describing 15 novel KCNK9 alterations from 47 KIS-affected individuals. We use clinical genetics and computer-assisted facial phenotyping to describe the phenotypic spectrum of KIS. We then interrogate the functional effects of the variants in the encoded TASK3 channel using sequence-based analysis, 3D molecular mechanic and dynamic protein modeling, and in vitro electrophysiological and functional methodologies. RESULTS: We describe the broader genetic and phenotypic variability for KIS in a cohort of individuals identifying an additional mutational hotspot at p.Arg131 and demonstrating the common features of this neurodevelopmental disorder to include motor and speech delay, intellectual disability, early feeding difficulties, muscular hypotonia, behavioral abnormalities, and dysmorphic features. The computational protein modeling and in vitro electrophysiological studies discover variability of the impact of KCNK9 variants on TASK3 channel function identifying variants causing gain and others causing loss of conductance. The most consistent functional impact of KCNK9 genetic variants, however, was altered channel regulation. CONCLUSIONS: This study extends our understanding of KIS mechanisms demonstrating its complex etiology including gain and loss of channel function and consistent loss of channel regulation. These data are rapidly applicable to diagnostic strategies, as KIS is not identifiable from clinical features alone and thus should be molecularly diagnosed. Furthermore, our data suggests unique therapeutic strategies may be needed to address the specific functional consequences of KCNK9 variation on channel function and regulation.


Subject(s)
Intellectual Disability , Potassium Channels, Tandem Pore Domain , Genotype , Humans , Intellectual Disability/genetics , Muscle Hypotonia , Mutation , Phenotype , Potassium Channels, Tandem Pore Domain/genetics , Potassium Channels, Tandem Pore Domain/metabolism
3.
Arch Dis Child ; 106(1): 31-37, 2021 01.
Article in English | MEDLINE | ID: mdl-32819910

ABSTRACT

OBJECTIVE: Use next-generation sequencing (NGS) technology to improve our diagnostic yield in patients with suspected genetic disorders in the Asian setting. DESIGN: A diagnostic study conducted between 2014 and 2019 (and ongoing) under the Singapore Undiagnosed Disease Program. Date of last analysis was 1 July 2019. SETTING: Inpatient and outpatient genetics service at two large academic centres in Singapore. PATIENTS: Inclusion criteria: patients suspected of genetic disorders, based on abnormal antenatal ultrasound, multiple congenital anomalies and developmental delay. EXCLUSION CRITERIA: patients with known genetic disorders, either after clinical assessment or investigations (such as karyotype or chromosomal microarray). INTERVENTIONS: Use of NGS technology-whole exome sequencing (WES) or whole genome sequencing (WGS). MAIN OUTCOME MEASURES: (1) Diagnostic yield by sequencing type, (2) diagnostic yield by phenotypical categories, (3) reduction in time to diagnosis and (4) change in clinical outcomes and management. RESULTS: We demonstrate a 37.8% diagnostic yield for WES (n=172) and a 33.3% yield for WGS (n=24). The yield was higher when sequencing was conducted on trios (40.2%), as well as for certain phenotypes (neuromuscular, 54%, and skeletal dysplasia, 50%). In addition to aiding genetic counselling in 100% of the families, a positive result led to a change in treatment in 27% of patients. CONCLUSION: Genomic sequencing is an effective method for diagnosing rare disease or previous 'undiagnosed' disease. The clinical utility of WES/WGS is seen in the shortened time to diagnosis and the discovery of novel variants. Additionally, reaching a diagnosis significantly impacts families and leads to alteration in management of these patients.


Subject(s)
Abnormalities, Multiple/genetics , Developmental Disabilities/genetics , High-Throughput Nucleotide Sequencing , Undiagnosed Diseases/genetics , Abnormalities, Multiple/diagnosis , Adolescent , Adult , Child , Child, Preschool , Developmental Disabilities/diagnosis , Female , Humans , Infant , Male , Singapore , Undiagnosed Diseases/diagnosis , Young Adult
5.
Genet Med ; 21(1): 207-212, 2019 01.
Article in English | MEDLINE | ID: mdl-29961769

ABSTRACT

PURPOSE: Genomic studies have demonstrated the necessity of ethnicity-specific population data to ascertain variant pathogenicity for disease diagnosis and treatment. This study examined the carrier prevalence of treatable inherited disorders (TIDs), where early diagnosis of at-risk offspring can significantly improve clinical outcomes. METHODS: Existing exome/ genome sequencing data of 831 Singaporeans were aggregated and examined for disease causing variants in 104 genes associated with 80 TIDs. RESULTS: Among the 831 Singaporean participants, genomic variant filtering and analysis identified 1 in 18 individuals (6%) to be carriers amongst one of 13 TIDs. Citrin deficiency and Wilson disease had the highest carrier frequency of 1 in 41, and 1 in 103 individuals, respectively. The pathogenic variants associated with citrin deficiency were 24 times more prevalent in our local cohorts when compared to Western cohorts. CONCLUSION: This study demonstrates the value of a population specific genomic database to determine true disease prevalence and has enabled the discovery of carrier frequencies of treatable genetic conditions specific to South East Asian populations, which are currently underestimated in existing data sources. This study framework can be adapted to other population groups and expanded to multiple genetic conditions to inform health policies directing precision medicine.


Subject(s)
Exome/genetics , Genetic Carrier Screening , Genetic Diseases, Inborn/genetics , Genetic Predisposition to Disease , Asia , Ethnicity , Gene Frequency , Genetic Diseases, Inborn/classification , Genetic Diseases, Inborn/epidemiology , Genetic Diseases, Inborn/pathology , Genetic Variation , Genetics, Population , Humans , Male , Metagenomics , Mutation/genetics , Precision Medicine
6.
Genet Med ; 20(12): 1692, 2018 12.
Article in English | MEDLINE | ID: mdl-30089799

ABSTRACT

At the time of publication the author Jyn Ling Kuan did not have a master's degree; this has now been amended to BSc. This has now been corrected in the PDF and HTML versions of the article.

7.
Clin Neurophysiol ; 128(5): 751-755, 2017 05.
Article in English | MEDLINE | ID: mdl-28319875

ABSTRACT

OBJECTIVE: To analyze patterns of nerve injury in pediatric ulnar neuropathy (PUN). METHODS: Retrospective analysis of 49 children with PUN. RESULTS: Sensory loss in digit V was the prevailing complaint (89%). Predominant localization was at the elbow (55%). Diminished ulnar SNAP was the most common abnormality (71%) with median axon loss estimate (MAXE) of 62%. Dorsal ulnar cutaneous (DUC) sensory nerve action potential (SNAP) was reduced in 55% with MAXE of 43%. Abductor digiti minimi (ADM) and first dorsal interosseous (FDI) compound muscle action potential (CMAP) were reduced half of the time, with MAXE of 30% and 28% respectively. There was high correlation between ulnar sensory MAXE and ADM MAXE (r=0.76, p<0.0001), FDI MAXE (r=0.81, p<0.0001) and DUC MAXE (r=0.60, p=0.0048). Neurogenic changes were seen in the ADM, FDI, flexor carpi ulnaris (FCU) and flexor digitorum profundus IV (FDP IV) in 79%, 77%, 25% and 35% respectively. Pathophysiology was demyelinating in 27%, axonal in 59% and mixed in 14%. CONCLUSIONS: In proximal axonal lesions, sensory fibers to digit V and motor fibers to distal muscles are predominantly affected, whereas in demyelinating lesions, slowing occurs twice as frequently as conduction block. SIGNIFICANCE: There is frequent axonal and fascicular injury in PUN.


Subject(s)
Action Potentials , Ulnar Neuropathies/physiopathology , Adolescent , Axons/pathology , Axons/physiology , Child , Female , Humans , Male , Motor Neurons/pathology , Motor Neurons/physiology , Muscle, Skeletal/growth & development , Muscle, Skeletal/innervation , Myelin Sheath/pathology , Reaction Time , Ulnar Nerve/physiopathology , Ulnar Neuropathies/pathology , Young Adult
8.
Muscle Nerve ; 55(5): 693-697, 2017 05.
Article in English | MEDLINE | ID: mdl-27615598

ABSTRACT

INTRODUCTION: We studied patterns of nerve injury in pediatric common fibular (peroneal) neuropathy (CFN). METHODS: A retrospective analysis was performed on data from 53 children with CFN at a pediatric electromyography laboratory. RESULTS: Conduction block at the fibular head was present in 35% of patients. Deep fibular axonal loss was identified in 77%, while superficial fibular axonal loss was identified in 45%. The pathophysiology was predominantly axonal in 72%, mostly demyelinating in 6%, and mixed in 22%. Predominantly demyelinating lesions at the fibular head demonstrated sparing of the superficial fibular sensory nerve (P = 0.01, Fischer exact test). Predominantly axonal lesions had a moderate correlation between superficial and deep fibular axonal loss (Spearman r = 0.52; P = 0.0001). CONCLUSIONS: There is frequent axonal and fascicular injury in pediatric CFN, similar to adults. Deep and superficial fibular nerve involvements correlate in axonal lesions, whereas superficial fibular sensory fibers are often spared in demyelinating lesions. Muscle Nerve, 2016 Muscle Nerve 55: 693-697, 2017.


Subject(s)
Action Potentials/physiology , Muscle, Skeletal/physiopathology , Neural Conduction/physiology , Peroneal Nerve/physiopathology , Peroneal Neuropathies/physiopathology , Adolescent , Axons/physiology , Child , Child, Preschool , Electromyography , Female , Humans , Infant , Male , Retrospective Studies , Young Adult
9.
J Pediatr ; 178: 227-232, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27567409

ABSTRACT

OBJECTIVE: To characterize the longitudinal clinical and electrophysiological patterns of thalidomide neuropathy in children and adolescents. STUDY DESIGN: Retrospective analysis of clinical records at a tertiary care children's hospital, including serial electrophysiological studies. RESULTS: Sixteen patients aged 6-24 years received thalidomide to treat Crohn's disease from 2002 to 2012. Nine subjects had electrophysiological evidence of sensorimotor axonal polyneuropathy, 8 of whom had sensory and/or motor symptoms. The patients with polyneuropathy received thalidomide for 5 weeks to 52 months, with cumulative doses ranging from 1.4 to 207.7 g. All subjects with cumulative doses greater than 60 g developed polyneuropathy, and 4 of the 5 subjects who received thalidomide for more than 20 months developed polyneuropathy. The 7 subjects who had normal neurophysiological studies received therapy for 1 week to 25 months, with cumulative doses ranging from 0.7 to 47 g. In contrast to some previous reports, several patients had sensorimotor polyneuropathies, rather than pure sensory neuropathies. In patients with neuropathy who received therapy for more than 24 months and had 3 or more electromyography studies, the severity of the neuropathy plateaued. CONCLUSIONS: Factors in addition to the total dose may contribute to the risk profile for thalidomide neuropathy, including pharmacogenetic susceptibilities. The severity of the neuropathy does not worsen relentlessly. Children, adolescents, and young adults receiving thalidomide should undergo regular neurophysiological studies to monitor for neuropathy.


Subject(s)
Crohn Disease/drug therapy , Immunosuppressive Agents/adverse effects , Peripheral Nervous System Diseases/chemically induced , Thalidomide/adverse effects , Adolescent , Child , Female , Humans , Longitudinal Studies , Male , Neural Conduction , Peripheral Nervous System Diseases/epidemiology , Retrospective Studies , Young Adult
10.
Am J Med Genet A ; 170(10): 2632-7, 2016 10.
Article in English | MEDLINE | ID: mdl-27151206

ABSTRACT

Patients with KCNK9 imprinting syndrome demonstrate congenital hypotonia, variable cleft palate, normal MRIs and EEGs, delayed development, and feeding problems. Associated facial dysmorphic features include dolichocephaly with bitemporal narrowing, short philtrum, tented upper lip, palatal abnormalities, and small mandible. This disorder maps to chromosomal region 8q24, and it is caused by a specific missense mutation 770G>A in exon 2, replacing glycine at position 236 by arginine (G236R) in the maternal copy of KCNK9 within this locus. KCNK9 (also called TASK3) encodes a member of the two pore- domain potassium channel (K2P) subfamily. This gene is normally imprinted with paternal silencing, thus a mutation in the maternal copy of the gene will result in disease, whereas a mutation in the paternal copy will have no effect. Exome sequencing in four new patients with developmental delay and central hypotonia revealed de novo G236R mutations. Older members of a previously reported Arab-Israeli family have intellectual disability of variable severity, persistent feeding difficulties in infancy with dysphagia of liquids and dysphonia with a muffled voice in early adulthood, generalized hypotonia, weakness of proximal muscles, elongated face with narrow bitemporal diameter, and reduced facial movements. We describe the clinical features in four recently recognized younger patients and compare them with those found in members of the originally reported Arab-Israeli family and suggest this may be a treatable disorder. © 2016 Wiley Periodicals, Inc.


Subject(s)
Genetic Diseases, Inborn/diagnosis , Genetic Diseases, Inborn/genetics , Genomic Imprinting , Potassium Channels, Tandem Pore Domain/genetics , Facies , Female , Genetic Diseases, Inborn/therapy , Humans , Infant , Male , Mutation , Phenotype
11.
EBioMedicine ; 5: 211-6, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27077130

ABSTRACT

BACKGROUND: In Western cohorts, the prevalence of incidental findings (IFs) or incidentalome, referring to variants in genes that are unrelated to the patient's primary condition, is between 0.86% and 8.8%. However, data on prevalence and type of IFs in Asian population is lacking. METHODS: In 2 cohorts of individuals with genomic sequencing performed in Singapore (total n = 377), we extracted and annotated variants in the 56 ACMG-recommended genes and filtered these variants based on the level of pathogenicity. We then analyzed the precise distribution of IFs, class of genes, related medical conditions, and potential clinical impact. RESULTS: We found a total of 41,607 variants in the 56 genes in our cohort of 377 individuals. After filtering for rare and coding variants, we identified 14 potential variants. After reviewing primary literature, only 4 out of the 14 variants were classified to be pathogenic, while an additional two variants were classified as likely pathogenic. Overall, the cumulative prevalence of IFs (pathogenic and likely pathogenic variants) in our cohort was 1.6%. CONCLUSION: The cumulative prevalence of IFs through genomic sequencing is low and the incidentalome may not be a significant barrier to implementation of genomics for personalized medicine.


Subject(s)
Genetic Variation , Genome, Human , Incidental Findings , Precision Medicine , Chromosome Mapping , Databases, Genetic , Exome/genetics , Genomics , High-Throughput Nucleotide Sequencing , Humans , Molecular Sequence Annotation , Mutation , Singapore
12.
Pediatr Neurol ; 52(5): 521-5, 2015 May.
Article in English | MEDLINE | ID: mdl-25746964

ABSTRACT

BACKGROUND: Anatomical localization of the rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) syndrome has proved elusive. Most patients had neuroimaging after cardiorespiratory collapse, revealing a range of ischemic lesions. PATIENT DESCRIPTION: A 15-year-old obese boy with an acute febrile encephalopathy had hypoventilation, autonomic dysfunction, visual hallucinations, hyperekplexia, and disordered body temperature, and saltwater regulation. These features describe the ROHHAD syndrome. Cerebrospinal fluid analysis showed pleocytosis, elevated neopterins, and oligoclonal bands, and serology for systemic and antineuronal antibodies was negative. He improved after receiving intravenous steroids, immunoglobulins, and long-term mycophenolate. Screening for neural crest tumors was negative. CONCLUSION: Magnetic resonance imaging of the brain early in his illness showed focal inflammation in the periaqueductal gray matter and hypothalamus. This unique localization explains almost all symptoms of this rare autoimmune encephalitis.


Subject(s)
Autonomic Nervous System Diseases/etiology , Hypothalamus/pathology , Hypoventilation/etiology , Obesity/complications , Obesity/pathology , Periaqueductal Gray/pathology , Adolescent , Humans , Magnetic Resonance Imaging , Male
13.
JAMA Neurol ; 71(5): 575-80, 2014 May.
Article in English | MEDLINE | ID: mdl-24590389

ABSTRACT

IMPORTANCE: Juvenile myasthenia gravis (MG) is a relatively rare autoimmune disorder. The comparative efficacy of plasmapheresis (PLEX) vs immunoglobulin as maintenance therapy is unclear for this childhood disease. OBJECTIVE: To determine whether PLEX or intravenous immunoglobulin (IVIG) therapy is more effective as maintenance therapy in this disease. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis over a 33-year period involved 54 children and adolescents with juvenile MG at a specialized neuromuscular clinic and electromyography laboratory at a tertiary care academic pediatric hospital. INTERVENTIONS: Plasmapheresis and IVIG. MAIN OUTCOMES AND MEASURES: Response to treatment was measured by both improvement in objective physical examination findings and the patients' reported improvement in symptoms and functional abilities. RESULTS: Subjective and objective outcomes correlated well. Both PLEX and IVIG had high response rates. Of the 27 patients with generalized juvenile MG receiving PLEX, IVIG, or both treatments, 7 of 7 patients treated with PLEX alone responded, 5 of 10 patients treated with IVIG alone responded, and 9 of 10 patients who received both responded. There was a significant difference in response rates between patients who received PLEX vs IVIG (P = .04). The youngest age at which PLEX was initiated via peripheral venous access was 9 years, while the youngest child who received IVIG was 9 months old. Thymectomy was performed in 17 children, of whom 11 experienced significant postoperative improvement. CONCLUSIONS AND RELEVANCE: This study provides class III evidence that PLEX and IVIG both have high response rates as maintenance therapies and are reasonable therapeutic options for juvenile MG. Plasmapheresis may have a more consistent response rate than IVIG in this setting. These findings will provide some guidance regarding the approach to therapy for juvenile MG, especially as the results differ somewhat from those of studies focusing on adult MG.


Subject(s)
Immunoglobulins, Intravenous/administration & dosage , Myasthenia Gravis/diagnosis , Myasthenia Gravis/therapy , Plasmapheresis/methods , Adolescent , Age Factors , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Male , Pyridostigmine Bromide/administration & dosage , Retrospective Studies
14.
Muscle Nerve ; 50(2): 244-9, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24375325

ABSTRACT

INTRODUCTION: Major advances in genetic analysis and neuroimaging have modified the traditional diagnostic approach for neuromuscular disorders. The purpose of this study was to investigate the role of electromyography (EMG) in the molecular era. METHODS: We retrospectively surveyed reports of all EMG studies performed at Boston Children's Hospital from 2001 through 2011. Data were collected on study numbers, patient ages, referring provider subspecialty, study indication, electrophysiological diagnosis, and study utility. RESULTS: A total of 2100 studies were performed. The volume increased from ~160 to ~250 studies/year. There was a trend toward studying older children. Neurologists, including neuromuscular specialists, constituted the major referral pool, whereas referrals from orthopedics increased steadily. Polyneuropathies followed by mononeuropathies were the most common indications and diagnoses. Fifty-seven percent of studies were normal. EMG provided meaningful information in 94% of cases. CONCLUSION: EMG continues to play a cardinal role in the diagnosis of pediatric neuromuscular disorders, although its practice paradigm is evolving.


Subject(s)
Electromyography , Neuromuscular Diseases/diagnosis , Pediatrics , Referral and Consultation/trends , Adolescent , Age Factors , Child , Child, Preschool , Female , Humans , Infant , Longitudinal Studies , Male , Neuromuscular Diseases/therapy , Retrospective Studies
15.
Curr Opin Pediatr ; 25(6): 682-8, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24240287

ABSTRACT

PURPOSE OF REVIEW: Spinal muscular atrophy (SMA) is a pediatric neuromuscular condition characterized by progressive proximal muscle weakness. It is one of the most common genetic causes of infant mortality across different races and is caused by mutation of the survival of motor neuron 1 (SMN1) gene on chromosome 5q13. RECENT FINDINGS: To date, there have been many therapeutics developments for SMA targeting various potential pathways such as increasing SMN gene expression, enhancing SMN2 exon 7 inclusion, neuroprotection, cell replacement, and gene therapy. SUMMARY: Although SMA remains an incurable disease to date, recent advances in the field of basic and translational research have enhanced our understanding of the pathogenesis of the disease and opened new possibilities for therapeutic intervention. This article reviews and highlights past and current translational research on SMA therapeutics.


Subject(s)
Genetic Therapy/methods , Muscular Atrophy, Spinal/drug therapy , Mutation/drug effects , Stem Cell Transplantation/methods , Survival of Motor Neuron 1 Protein/drug effects , Animals , Child , Child, Preschool , Disease Models, Animal , Drug Design , Female , Genetic Therapy/trends , Humans , Hydroxyurea/therapeutic use , Male , Mice , Muscular Atrophy, Spinal/genetics , Muscular Atrophy, Spinal/pathology , Mutation/genetics , Nerve Tissue Proteins/genetics , Neuroprotective Agents/pharmacology , Stem Cell Transplantation/trends , Survival of Motor Neuron 1 Protein/genetics , Survival of Motor Neuron 1 Protein/metabolism , Survival of Motor Neuron 2 Protein/drug effects , Survival of Motor Neuron 2 Protein/genetics , Survival of Motor Neuron 2 Protein/metabolism , Valproic Acid/therapeutic use
16.
Curr Opin Pediatr ; 25(6): 694-700, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24141560

ABSTRACT

PURPOSE OF REVIEW: Juvenile myasthenia gravis is a relatively rare autoimmune neuromuscular disorder. The pathophysiology of juvenile myasthenia gravis is similar to that of adult myasthenia gravis, though there remain important differences regarding presentation and therapeutic options. We review the pathophysiology, clinical presentation, and treatment options for juvenile myasthenia gravis. RECENT FINDINGS: Randomized clinical studies of myasthenia gravis have been carried out primarily in adult populations. As juvenile myasthenia gravis is rare, it has been difficult to collect prospective randomized controlled data to evaluate treatment outcomes and efficacy. A recent retrospective series suggests that, as in adult myasthenia gravis, thymectomy is a viable therapeutic option for selected cases of generalized juvenile myasthenia gravis. This is corroborated by the clinical experience of the authors in a referral center with a cohort of patients affected by juvenile myasthenia gravis over a number of years. SUMMARY: Recent studies illustrate that some, but not all, adult research on myasthenia gravis is applicable to children and adolescents with juvenile myasthenia gravis. Adult research can inform pediatric studies, but should not be regarded as a substitute for dedicated research in those populations.


Subject(s)
Electromyography , Immunoglobulins, Intravenous/therapeutic use , Myasthenia Gravis, Neonatal/diagnosis , Myasthenia Gravis, Neonatal/drug therapy , Myasthenic Syndromes, Congenital/diagnosis , Thymectomy , Age of Onset , Child , Child, Preschool , Cholinesterase Inhibitors/therapeutic use , Female , Glucocorticoids/therapeutic use , Humans , Immunosuppression Therapy , Infant , Male , Myasthenia Gravis, Neonatal/physiopathology , Myasthenia Gravis, Neonatal/surgery , Myasthenic Syndromes, Congenital/drug therapy , Myasthenic Syndromes, Congenital/physiopathology , Plasmapheresis , Pyridostigmine Bromide/therapeutic use , Randomized Controlled Trials as Topic , Thymectomy/methods
18.
Ther Adv Neurol Disord ; 6(3): 147-60, 2013 May.
Article in English | MEDLINE | ID: mdl-23634188

ABSTRACT

Pediatric neuromuscular disorders comprise a large variety of disorders that can be classified based on their neuroanatomical localization, patterns of weakness, and laboratory test results. Over the last decade, the field of translational research has been active with many ongoing clinical trials. This is particularly so in two common pediatric neuromuscular disorders: Duchenne muscular dystrophy and spinal muscular atrophy. Although no definitive therapy has yet been found, numerous active areas of research raise the potential for novel therapies in these two disorders, offering hope for improved quality of life and life expectancy for affected individuals.

19.
JAMA Neurol ; 70(6): 788-91, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23699708

ABSTRACT

IMPORTANCE: Ataxia in children is a diagnostic challenge. Besides the more common acquired causes of ataxia, there are more than 50 inherited disorders associated with ataxia. Our objective was to highlight whole-exome sequencing as a rapidly evolving clinical tool for diagnosis of mendelian disorders, and we illustrate this in the report of a single case of a novel sequence variation in the SACS gene. OBSERVATIONS: A 4-year-old girl presented with delayed gross motor development, ataxia, and polyneuropathy. Results of initial testing for the common causes of inherited and acquired ataxia were unrevealing. Whole-exome sequencing showed a novel frameshift homozygous sequence variation in the SACS gene, consistent with the diagnosis of autosomal recessive spastic ataxia of Charlevoix-Saguenay. CONCLUSIONS: Whole-exome sequencing is a powerful clinical tool that has been increasingly used to assist in the diagnosis of mendelian disorders. It provides a cost-effective, efficient, and expedited approach to making a clinical diagnosis and, in some cases, may be the only way to make a diagnosis.


Subject(s)
Exome/genetics , Genetic Variation/genetics , Muscle Spasticity/diagnosis , Muscle Spasticity/genetics , Sequence Analysis, DNA , Spinocerebellar Ataxias/congenital , Child, Preschool , Female , Humans , Sequence Analysis, DNA/methods , Spinocerebellar Ataxias/diagnosis , Spinocerebellar Ataxias/genetics
20.
Cardiovasc Intervent Radiol ; 36(4): 1165-71, 2013 Aug.
Article in English | MEDLINE | ID: mdl-22956046

ABSTRACT

Ethanol is often used in sclerotherapy to treat vascular malformations. Nerve injury is a known complication of this procedure. However, the management of this complication is not well described in literature. This case describes a 10-year-old boy with a slow flow vascular malformation in the right calf who underwent transarterial ethanol embolization following prior unsuccessful direct percutaneous sclerotherapy. The development of a dense foot drop that subsequently recovered is described, and the management of this uncommon but distressful complication is discussed.


Subject(s)
Embolization, Therapeutic/adverse effects , Ethanol/adverse effects , Gait Disorders, Neurologic/etiology , Lower Extremity/blood supply , Peripheral Nerve Injuries/etiology , Vascular Malformations/therapy , Child , Embolization, Therapeutic/methods , Ethanol/therapeutic use , Follow-Up Studies , Gait Disorders, Neurologic/physiopathology , Gait Disorders, Neurologic/therapy , Humans , Magnetic Resonance Angiography/methods , Male , Muscle, Skeletal/blood supply , Peripheral Nerve Injuries/physiopathology , Peripheral Nerve Injuries/therapy , Retreatment , Risk Assessment , Sclerotherapy/adverse effects , Sclerotherapy/methods , Treatment Failure , Treatment Outcome , Vascular Malformations/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...